Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Fertil Steril ; 104(6): 1435-41, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26348275

RESUMEN

OBJECTIVE: To determine live-birth rates (LBRs) at various ages in very poor prognosis patients, who are defined as poor responders under the Bologna criteria. DESIGN: Retrospective cohort study. SETTING: Academically affiliated private fertility center. PATIENT(S): Among 483 patients, who under the Bologna criteria (three or fewer oocytes, >40 years of age, and/or antimüllerian hormone [AMH] <1.1 ng/mL [2/3 criteria minimum]) were poor responders, 278 (381 fresh IVF cycles) qualified for the study because they had at least one embryo on day 3 for transfer. INTERVENTION(S): IVF cycles in women with low functional ovarian reserve, involving androgen and CoQ10 supplementation and ovarian stimulation with daily gonadotropin dosages of 300-450 IU of FSH and 150 IU of hMG in microdose agonist cycles. MAIN OUTCOME MEASURE(S): Age-specific LBRs per ET. RESULT(S): Ages did not differ between nonelective (ne) single ET (SET), ne2-ET, and ne ≥ 3-ET cycles (41.3 ± 3.9, 41.7 ± 3.1, and 42.4 ± 2.1 years, respectively). Patients with neSETs demonstrated significantly lower AMH and higher FSH levels and required higher gonadotropin dosages than ne2-ET and ne ≥ 3-ET patients. LBRs declined with age. Above age 42, three or more embryos are required to achieve reasonable LBRs and two or more to avoid futility under American Society for Reproductive Medicine (ASRM) guidelines. CONCLUSION(S): Very poor prognosis patients can still achieve acceptable pregnancy rates at least till their mid-40s if they reach ET. The degree to which egg donation is emphasized as the only treatment option in such patients, therefore, requires reconsideration. Above age 42, at least two, and preferably three embryos, are however required to exceed futility, as defined by ASRM.


Asunto(s)
Fármacos para la Fertilidad Femenina/uso terapéutico , Infertilidad Femenina/terapia , Nacimiento Vivo , Ovario/efectos de los fármacos , Inducción de la Ovulación/métodos , Ovulación/efectos de los fármacos , Transferencia de un Solo Embrión , Adulto , Factores de Edad , Hormona Antimülleriana/sangre , Biomarcadores/sangre , Femenino , Fertilidad , Fármacos para la Fertilidad Femenina/efectos adversos , Fertilización In Vitro , Humanos , Infertilidad Femenina/sangre , Infertilidad Femenina/diagnóstico , Infertilidad Femenina/fisiopatología , Recuperación del Oocito , Ovario/metabolismo , Ovario/fisiopatología , Inducción de la Ovulación/efectos adversos , Embarazo , Índice de Embarazo , Estudios Retrospectivos , Factores de Riesgo , Transferencia de un Solo Embrión/efectos adversos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA